|
1
|
Tabouret E, Chinot O, Metellus P, Tallet
A, Viens P and Gonçalves A: Recent trends in epidemiology of brain
metastases: An overview. Anticancer Res. 32:4655–4662.
2012.PubMed/NCBI
|
|
2
|
Kamath SD and Kumthekar PU: Immune
Checkpoint Inhibitors for the Treatment of Central Nervous System
(CNS) Metastatic Disease. Front Oncol. 8:4142018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hartgerink D, van der Heijden B, De
Ruysscher D, Postma A, Ackermans L, Hoeben A, Anten M, Lambin P,
Terhaag K, Jochems A, et al: Stereotactic Radiosurgery in the
Management of Patients With Brain Metastases of Non-Small Cell Lung
Cancer: Indications, Decision Tools and Future Directions. Front
Oncol. 8:1542018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sevenich L: Turning 'Cold' Into 'Hot'
Tumors-Opportunities and Challenges for Radio-Immunotherapy Against
Primary and Metastatic Brain Cancers. Front Oncol. 9:1632019.
View Article : Google Scholar
|
|
5
|
Akhavan D, Alizadeh D, Wang D, Weist MR,
Shepphird JK and Brown CE: CAR T cells for brain tumors: Lessons
learned and road ahead. Immunol Rev. 290:60–84. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Keskin DB, Anandappa AJ, Sun J, Tirosh I,
Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E,
et al: Neoantigen vaccine generates intratumoral T cell responses
in phase Ib glio-blastoma trial. Nature. 565:234–239. 2019.
View Article : Google Scholar
|
|
7
|
Majzner RG, Theruvath JL, Nellan A,
Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota
C, et al: CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen,
Demonstrate Potent Preclinical Activity Against Pediatric Solid
Tumors and Brain Tumors. Clin Cancer Res. 25:2560–2574. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iorgulescu JB, Harary M, Zogg CK, Ligon
KL, Reardon DA, Hodi FS, Aizer AA and Smith TR: Improved
Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of
Checkpoint Blockade Immunotherapies: Results from a National
Cohort. Cancer Immunol Res. 6:1039–1045. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Di Giacomo AM, Ascierto PA, Queirolo P,
Pilla L, Ridolfi R, Santinami M, Testori A, Simeone E, Guidoboni M,
Maurichi A, et al: Three-year follow-up of advanced melanoma
patients who received ipilimumab plus fotemustine in the Italian
Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann Oncol.
26:798–803. 2015. View Article : Google Scholar
|
|
10
|
Lauko A, Thapa B, Venur VA and Ahluwalia
MS: Management of Brain Metastases in the New Era of Checkpoint
Inhibition. Curr Neurol Neurosci Rep. 18:702018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sharpe AH and Pauken KE: The diverse
functions of the PD1 inhibitory pathway. Nat Rev Immunol.
18:153–167. 2018. View Article : Google Scholar
|
|
12
|
Seidel JA, Otsuka A and Kabashima K:
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of
Action, Efficacy, and Limitations. Front Oncol. 8:862018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Goodman AM, Kato S, Bazhenova L, Patel SP,
Frampton GM, Miller V, Stephens PJ, Daniels GA and Kurzrock R:
Tumor Mutational Burden as an Independent Predictor of Response to
Immunotherapy in Diverse Cancers. Mol Cancer Ther. 16:2598–2608.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Omuro A, Vlahovic G, Lim M, Sahebjam S,
Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL,
Latek R, et al: Nivolumab with or without ipilimumab in patients
with recurrent glioblastoma: Results from exploratory phase I
cohorts of CheckMate 143. Neurooncol. 20:674–686. 2018.
|
|
15
|
Banks WA: From blood-brain barrier to
blood-brain interface: New opportunities for CNS drug delivery. Nat
Rev Drug Discov. 15:275–292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kipnis J: Multifaceted interactions
between adaptive immunity and the central nervous system. Science.
353:766–771. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sampson JH, Maus MV and June CH:
Immunotherapy for Brain Tumors. J Clin Oncol. 35:2450–2456. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Engelhardt B, Vajkoczy P and Weller RO:
The movers and shapers in immune privilege of the CNS. Nat Immunol.
18:123–131. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Preusser M, Lim M, Hafler DA, Reardon DA
and Sampson JH: Prospects of immune checkpoint modulators in the
treatment of glioblastoma. Nat Rev Neurol. 11:504–514. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
El Rassy E, Farhat F and Kattan J: The
forgotten role of adjuvant immune checkpoint inhibitors in
preventing melanoma brain metastasis. Immunotherapy. 10:1289–1291.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Koelzer VH, Rothschild SI, Zihler D, Wicki
A, Willi B, Willi N, Voegeli M, Cathomas G, Zippelius A and Mertz
KD: Systemic inflammation in a melanoma patient treated with immune
checkpoint inhibitors-an autopsy study. J Immunother Cancer.
4:132016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Berghoff AS, Fuchs E, Ricken G, Mlecnik B,
Bindea G, Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D,
et al: Density of tumor-infiltrating lymphocytes correlates with
extent of brain edema and overall survival time in patients with
brain metastases. OncoImmunology. 5:e10573882015. View Article : Google Scholar
|
|
23
|
Kluger HM, Zito CR, Barr ML, Baine MK,
Chiang VL, Sznol M, Rimm DL, Chen L and Jilaveanu LB:
Characterization of PD-L1 Expression and Associated T-cell
Infiltrates in Metastatic Melanoma Samples from Variable Anatomic
Sites. Clin Cancer Res. 21:3052–3060. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Abate-Daga D, Ramello MC, Smalley I,
Forsyth PA and Smalley KSM: The biology and therapeutic management
of melanoma brain metastases. Biochem Pharmacol. 153:35–45. 2018.
View Article : Google Scholar :
|
|
25
|
Lehrer EJ, McGee HM, Peterson JL, Vallow
L, Ruiz-Garcia H, Zaorsky NG, Sharma S and Trifiletti DM:
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors in the
Management of Brain Metastases. Int J Mol Sci. 19:30542018.
View Article : Google Scholar :
|
|
26
|
Darvin P, Toor SM, Sasidharan Nair V and
Elkord E: Immune checkpoint inhibitors: Recent progress and
potential biomarkers. Exp Mol Med. 50:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eggermont AM, Chiarion-Sileni V, Grob JJ,
Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA,
Richards JM, et al: Adjuvant ipilimumab versus placebo after
complete resection of high-risk stage III melanoma (EORTC 18071): A
randomised, double-blind, phase 3 trial. Lancet Oncol. 16:522–530.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Leighl NB, Hellmann MD, Hui R, Carcereny
E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L,
et al: Pembrolizumab in patients with advanced non-small-cell lung
cancer (KEYNOTE-001): 3-year results from an open-label, phase 1
study. Lancet Respir Med. 7:347–357. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Horn L, Spigel DR, Vokes EE, Holgado E,
Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L,
et al: Nivolumab Versus Docetaxel in Previously Treated Patients
With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From
Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and
CheckMate 057). J Clin Oncol. 35:3924–3933. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Larkin J, Hodi FS and Wolchok JD: Combined
Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N
Engl J Med. 373:1270–1271. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus Docetaxel in Advanced
Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Topalian SLF, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lanier CM, Hughes R, Ahmed T, LeCompte M,
Masters AH, Petty WJ, Ruiz J, Triozzi P, Su J, O'Neill S, et al:
Immunotherapy is associated with improved survival and decreased
neurologic death after SRS for brain metastases from lung and
melanoma primaries. Neurooncol Pract. 6:402–409. 2019.PubMed/NCBI
|
|
34
|
Rossi S, Finocchiaro G, Marchetti S,
Toschi L and Santoro A: Checkpoint inhibitors: 'raising the bar'
also in brain metastases from non-small-cell lung cancer?
Immunotherapy. 10:403–410. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Margolin K, Ernstoff MS, Hamid O, Lawrence
D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF,
et al: Ipilimumab in patients with melanoma and brain metastases:
An open-label, phase 2 trial. Lancet Oncol. 13:459–465. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Di Giacomo AM, Ascierto PA, Pilla L,
Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L,
Simeone E, Nicoletti SV, et al: Ipilimumab and fotemustine in
patients with advanced melanoma (NIBIT-M1): An open-label,
single-arm phase 2 trial. Lancet Oncol. 13:879–886. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Queirolo P, Spagnolo F, Ascierto PA,
Simeone E, Marchetti P, Scoppola A, Del Vecchio M, Di Guardo L,
Maio M, Di Giacomo AM, et al: Efficacy and safety of ipilimumab in
patients with advanced melanoma and brain metastases. J Neurooncol.
118:109–116. 2014.PubMed/NCBI
|
|
38
|
Goldberg SB, Gettinger SN, Mahajan A,
Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A,
Jilaveanu L, et al: Pembrolizumab for patients with melanoma or
non-small-cell lung cancer and untreated brain metastases: Early
analysis of a non-randomised, open-label, phase 2 trial. Lancet
Oncol. 17:976–983. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kluger HM, Chiang V, Mahajan A, Zito CR,
Sznol M, Tran T, Weiss SA, Cohen JV, Yu J, Hegde U, et al:
Long-Term Survival of Patients With Melanoma With Active Brain
Metastases Treated With Pembrolizumab on a Phase II Trial. J Clin
Oncol. 37:52–60. 2019. View Article : Google Scholar :
|
|
40
|
Gandhi L, Rodríguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al KEYNOTE-189 Investigators: Pembrolizumab plus
Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J
Med. 378:2078–2092. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Goldman JW, Crino L, Vokes EE, Holgado E,
Reckamp K, Pluzanski A, Spigel D, Kohlhaeufl M, Garassino M, Chow
LQ, et al: P2.36: Nivolumab (nivo) in Patients (pts) With Advanced
(adv) NSCLC and Central Nervous System (CNS) Metastases (mets):
Track: Immunotherapy. J Thorac Oncol Off Publ Int Assoc Study Lung
Cancer. 11:S238–S239. 2016.
|
|
42
|
Long GV, Atkinson V, Lo S, Sandhu S,
Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer
RA, et al: Combination nivolumab and ipilimumab or nivolumab alone
in melanoma brain metastases: A multicentre randomised phase 2
study. Lancet Oncol. 19:672–681. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Crinò L, Bronte G, Bidoli P, Cravero P,
Minenza E, Cortesi E, Garassino MC, Proto C, Cappuzzo F, Grossi F,
et al: Nivolumab and brain metastases in patients with advanced
non-squamous non-small cell lung cancer. Lung Cancer. 129:35–40.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bracarda S, Galli L, Maruzzo M, Lo Re G,
Buti S, Favaretto A, Di Costanzo F, Sacco C, Merlano M, Mucciarini
C, et al: Negative prognostic factors and resulting clinical
outcome in patients with metastatic renal cell carcinoma included
in the Italian nivolumab-expanded access program. Future Oncol.
14:1347–1354. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gadgeel SM, Lukas RV, Goldschmidt J,
Conkling P, Park K, Cortinovis D, de Marinis F, Rittmeyer A, Patel
JD, von Pawel J, et al: Atezolizumab in patients with advanced
non-small cell lung cancer and history of asymptomatic, treated
brain metastases: Exploratory analyses of the phase III OAK study.
Lung Cancer. 128:105–112. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tawbi HA, Forsyth PA, Algazi A, Hamid O,
Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, et
al: Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the
Brain. N Engl J Med. 379:722–730. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Franceschini D, Franzese C, Navarria P,
Ascolese AM, De Rose F, Del Vecchio M, Santoro A and Scorsetti M:
Radiotherapy and immunotherapy: Can this combination change the
prognosis of patients with melanoma brain metastases? Cancer Treat
Rev. 50:1–8. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zindler JD, Slotman BJ and Lagerwaard FJ:
Patterns of distant brain recurrences after radiosurgery alone for
newly diagnosed brain metastases: Implications for salvage therapy.
Radiother Oncol. 112:212–216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Golden EB, Pellicciotta I, Demaria S,
Barcellos-Hoff MH and Formenti SC: The convergence of radiation and
immunogenic cell death signaling pathways. Front Oncol. 2:882012.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ngwa W, Irabor OC, Schoenfeld JD, Hesser
J, Demaria S and Formenti SC: Using immunotherapy to boost the
abscopal effect. Nat Rev Cancer. 18:313–322. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lee Y, Auh SL, Wang Y, Burnette B, Wang Y,
Meng Y, Beckett M, Sharma R, Chin R, Tu T, et al: Therapeutic
effects of ablative radiation on local tumor require
CD8+ T cells: Changing strategies for cancer treatment.
Blood. 114:589–595. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Grass GD, Krishna N and Kim S: The immune
mechanisms of abscopal effect in radiation therapy. Curr Probl
Cancer. 40:10–24. 2016. View Article : Google Scholar
|
|
53
|
Reits EA, Hodge JW, Herberts CA, Groothuis
TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH,
Neijssen J, et al: Radiation modulates the peptide repertoire,
enhances MHC class I expression, and induces successful antitumor
immunotherapy. J Exp Med. 203:1259–1271. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Matsumura S, Wang B, Kawashima N,
Braunstein S, Badura M, Cameron TO, Babb JS, Schneider RJ, Formenti
SC, Dustin ML, et al: Radiation-induced CXCL16 release by breast
cancer cells attracts effector T cells. J Immunol. 181:3099–3107.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Schaue D, Kachikwu EL and McBride WH:
Cytokines in radio-biological responses: A review. Radiat Res.
178:505–523. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Sato H, Niimi A, Yasuhara T, Permata TBM,
Hagiwara Y, Isono M, Nuryadi E, Sekine R, Oike T, Kakoti S, et al:
DNA double-strand break repair pathway regulates PD-L1 expression
in cancer cells. Nat Commun. 8:17512017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Herbst RS, Soria JC, Kowanetz M, Fine GD,
Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger
SN, et al: Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kiess AP, Wolchok JD, Barker CA, Postow
MA, Tabar V, Huse JT, Chan TA, Yamada Y and Beal K: Stereotactic
radiosurgery for melanoma brain metastases in patients receiving
ipilimumab: Safety profile and efficacy of combined treatment. Int
J Radiat Oncol Biol Phys. 92:368–375. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Cohen-Inbar O, Shih HH, Xu Z, Schlesinger
D and Sheehan JP: The effect of timing of stereotactic radiosurgery
treatment of melanoma brain metastases treated with ipilimumab. J
Neurosurg. 127:1007–1014. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Diao K, Bian SX, Routman DM, Yu C, Kim PE,
Wagle NA, Wong MK, Zada G and Chang EL: Combination ipilimumab and
radiosurgery for brain metastases: Tumor, edema, and adverse
radiation effects. J Neurosurg. 129:1397–1406. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Acharya S, Mahmood M, Mullen D, Yang D,
Tsien CI, Huang J, Perkins SM, Rich K, Chicoine M, Leuthardt E, et
al: Distant intracranial failure in melanoma brain metastases
treated with stereotactic radiosurgery in the era of immunotherapy
and targeted agents. Adv Radiat Oncol. 2:572–580. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Choong ES, Lo S, Drummond M, Fogarty GB,
Menzies AM, Guminski A, Shivalingam B, Clarke K, Long GV and Hong
AM: Survival of patients with melanoma brain metastasis treated
with stereotactic radiosurgery and active systemic drug therapies.
Eur J Cancer. 75:169–178. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Williams NL, Wuthrick EJ, Kim H, Palmer
JD, Garg S, Eldredge-Hindy H, Daskalakis C, Feeney KJ, Mastrangelo
MJ, Kim LJ, et al: Phase 1 Study of Ipilimumab Combined With Whole
Brain Radiation Therapy or Radiosurgery for Melanoma Patients With
Brain Metastases. Int J Radiat Oncol Biol Phys. 99:22–30. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chen L, Douglass J, Kleinberg L, Ye X,
Marciscano AE, Forde PM, Brahmer J, Lipson E, Sharfman W, Hammers
H, et al: Concurrent Immune Checkpoint Inhibitors and Stereotactic
Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer,
Melanoma, and Renal Cell Carcinoma. Int J Radiat Oncol Biol Phys.
100:916–925. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Qian JM, Yu JB, Kluger HM and Chiang VL:
Timing and type of immune checkpoint therapy affect the early
radiographic response of melanoma brain metastases to stereotactic
radio-surgery. Cancer. 122:3051–3058. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
An Y, Jiang W, Kim BYS, Qian JM, Tang C,
Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, et al: Stereotactic
radio-surgery of early melanoma brain metastases after initiation
of anti-CTLA-4 treatment is associated with improved intracranial
control. Radiother Oncol. 125:80–88. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Postow MA, Sidlow R and Hellmann MD:
Immune-Related Adverse Events Associated with Immune Checkpoint
Blockade. N Engl J Med. 378:158–168. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Weber JS, Hodi FS, Wolchok JD, Topalian
SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, et
al: Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of
Patients With Advanced Melanoma. J Clin Oncol. 35:785–792. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Nieder C and Hodi FS: Ipilimumab in
patients with melanoma and brain metastases. Lancet Oncol.
13:e277–e278; author reply e277-e278. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wolchok JD, Neyns B, Linette G, Negrier S,
Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie
T Jr, et al: Ipilimumab monotherapy in patients with pretreated
advanced melanoma: A randomised, double-blind, multicentre, phase
2, dose-ranging study. Lancet Oncol. 11:155–164. 2010. View Article : Google Scholar
|
|
71
|
Topalian SL, Sznol M, McDermott DF, Kluger
HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB,
Powderly JD, et al: Survival, durable tumor remission, and
long-term safety in patients with advanced melanoma receiving
nivolumab. J Clin Oncol. 32:1020–1030. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Robert C, Ribas A, Wolchok JDF, Hodi FS,
Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, et
al: Anti-p rogrammed-death-receptor-1 treatment with pembrolizumab
in ipilimumab-refractory advanced melanoma: A randomised
dose-comparison cohort of a phase 1 trial. Lancet. 384:1109–1117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ribas A, Puzanov I, Dummer R, Schadendorf
D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD,
et al: Pembrolizumab versus investigator-choice chemotherapy for
ipilimumab-refractory melanoma (KEYNOTE-002): A randomised,
controlled, phase 2 trial. Lancet Oncol. 16:908–918. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Anderson ES, Postow MA, Wolchok JD, Young
RJ, Ballangrud Å, Chan TA, Yamada Y and Beal K: Melanoma brain
metastases treated with stereotactic radiosurgery and concurrent
pembro-lizumab display marked regression; efficacy and safety of
combined treatment. J Immunother Cancer. 5:762017. View Article : Google Scholar
|
|
75
|
Liniker E, Menzies AM, Kong BY, Cooper A,
Ramanujam S, Lo S, Kefford RF, Fogarty GB, Guminski A, Wang TW, et
al: Activity and safety of radiotherapy with anti-PD-1 drug therapy
in patients with metastatic melanoma. OncoImmunology.
5:e12147882016. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Gerber NK, Young RJ, Barker CA, Wolchok
JD, Chan TA, Yamada Y, Friguglietti L and Beal K: Ipilimumab and
whole brain radiation therapy for melanoma brain metastases. J
Neurooncol. 121:159–165. 2015. View Article : Google Scholar
|
|
77
|
Baskar R, Dai J, Wenlong N, Yeo R and Yeoh
KW: Biological response of cancer cells to radiation treatment.
Front Mol Biosci. 1:242014. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Colaco RJ, Martin P, Kluger HM, Yu JB and
Chiang VL: Does immunotherapy increase the rate of radiation
necrosis after radiosurgical treatment of brain metastases? J
Neurosurg. 125:17–23. 2016. View Article : Google Scholar
|
|
79
|
Martin AM, Cagney DN, Catalano PJ,
Alexander BM, Redig AJ, Schoenfeld JD and Aizer AA: Immunotherapy
and Symptomatic Radiation Necrosis in Patients With Brain
Metastases Treated With Stereotactic Radiation. JAMA Oncol.
4:1123–1124. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Patel KR, Shoukat S, Oliver DE, Chowdhary
M, Rizzo M, Lawson DH, Khosa F, Liu Y and Khan MK: Ipilimumab and
Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone
for Newly Diagnosed Melanoma Brain Metastases. Am J Clin Oncol.
40:444–450. 2017. View Article : Google Scholar
|
|
81
|
Kaidar-Person O, Zagar TM, Deal A, Moschos
SJ, Ewend MG, Sasaki-Adams D, Lee CB, Collichio FA, Fried D, Marks
LB, et al: The incidence of radiation necrosis following
stereotactic radiotherapy for melanoma brain metastases: The
potential impact of immunotherapy. Anticancer Drugs. 28:669–675.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Silk AW, Bassetti MF, West BT, Tsien CI
and Lao CD: Ipilimumab and radiation therapy for melanoma brain
metastases. Cancer Med. 2:899–906. 2013. View Article : Google Scholar
|
|
83
|
Mathew M, Tam M, Ott PA, Pavlick AC, Rush
SC, Donahue BR, Golfinos JG, Parker EC, Huang PP and Narayana A:
Ipilimumab in melanoma with limited brain metastases treated with
stereo-tactic radiosurgery. Melanoma Res. 23:191–195. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Stupp R, Taillibert S, Kanner AA, Kesari
S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink
KL, et al: Maintenance Therapy With Tumor-Treating Fields Plus
Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized
Clinical Trial. JAMA. 314:2535–2543. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Wong ET, Lok E and Swanson KD: Clinical
benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and
TCCC after temozolomide and bevacizumab failure: A preliminary
observation. Cancer Med. 4:383–391. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Roselli E, Frieling JS, Thorner K, Ramello
MC, Lynch CC and Abate-Daga D: CAR T Engineering: Optimizing Signal
Transduction and Effector Mechanisms. BioDrugs: clinical
immunotherapeutics, biopharmaceuticals and gene therapy. BioDrugs.
33:647–659. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Rice J, Nagle S, Randall J and Hinson HE:
Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms,
Clinical Presentation, and Approach to Treatment. Curr Treat
Options Neurol. 21:402019. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Till BG, Jensen MC, Wang J, Chen EY, Wood
BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ, et al:
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle
cell lymphoma using genetically modified autologous CD20-specific T
cells. Blood. 112:2261–2271. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Kershaw MH, Westwood JA, Parker LL, Wang
G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S,
Rogers-Freezer L, et al: A phase I study on adoptive immunotherapy
using gene-modified T cells for ovarian cancer. Clin Cancer Res.
12:6106–6115. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Maus MV and June CH: Making Better
Chimeric Antigen Receptors for Adoptive T-cell Therapy. Clin Cancer
Res. 22:1875–1884. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Maude SL, Frey N, Shaw PA, Aplenc R,
Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et
al: Chimeric antigen receptor T cells for sustained remissions in
leukemia. N Engl J Med. 371:1507–1517. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Holzinger A, Barden M and Abken H: The
growing world of CAR T cell trials: A systematic review. Cancer
Immunol Immunother. 65:1433–1450. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Newick K, O'Brien S, Moon E and Albelda
SM: CAR T Cell Therapy for Solid Tumors. Annu Rev Med. 68:139–152.
2017. View Article : Google Scholar
|
|
94
|
Lee DW, Kochenderfer JN, Stetler-Stevenson
M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M,
Shah NN, et al: T cells expressing CD19 chimeric antigen receptors
for acute lymphoblastic leukaemia in children and young adults: A
phase 1 dose-escalation trial. Lancet. 385:517–528. 2015.
View Article : Google Scholar
|
|
95
|
Brown CE, Alizadeh D, Starr R, Weng L,
Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J,
Simpson J, et al: Regression of Glioblastoma after Chimeric Antigen
Receptor T-Cell Therapy. N Engl J Med. 375:2561–2569. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Abramson JS, McGree B, Noyes S, Plummer S,
Wong C, Chen YB, Palmer E, Albertson T, Ferry JA and
Arrillaga-Romany IC: Anti-CD19 CAR T Cells in CNS Diffuse
Large-B-Cell Lymphoma. N Engl J Med. 377:783–784. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Brown CE, Badie B, Barish ME, Weng L,
Ostberg JR, Chang WC, Naranjo A, Starr R, Wagner J, Wright C, et
al: Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen
Receptor CD8+ T Cells in Patients with Recurrent
Glioblastoma. Clin Cancer Res. 21:4062–4072. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
O'Rourke DM, Nasrallah MP, Desai A,
Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem
S, Maloney E, Shen A, et al: A single dose of peripherally infused
EGFRvIII-directed CAR T cells mediates antigen loss and induces
adaptive resistance in patients with recurrent glio-blastoma. Sci
Transl Med. 9:eaaa09842017. View Article : Google Scholar
|
|
99
|
Ahmed N, Brawley V, Hegde M, Bielamowicz
K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, et
al: HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific
T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation
Trial. JAMA Oncol. 3:1094–1101. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Priceman SJ, Tilakawardane D, Jeang B,
Aguilar B, Murad JP, Park AK, Chang W-C, Ostberg JR, Neman J,
Jandial R, et al: Regional Delivery of Chimeric Antigen
Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer
Metastasis to the Brain. Clin Cancer Res. 24:95–105. 2018.
View Article : Google Scholar
|
|
101
|
Reardon DA and Mitchell DA: The
development of dendritic cell vaccine-based immunotherapies for
glioblastoma. Semin Immunopathol. 39:225–239. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Li M, Han S and Shi X: In situ dendritic
cell vaccination for the treatment of glioma and literature review.
Tumour Biol. 37:1797–1801. 2016. View Article : Google Scholar
|
|
103
|
Kyte JA, Mu L, Aamdal S, Kvalheim G,
Dueland S, Hauser M, Gullestad HP, Ryder T, Lislerud K, Hammerstad
H, et al: Phase I/II trial of melanoma therapy with dendritic cells
transfected with autologous tumor-mRNA. Cancer Gene Ther.
13:905–918. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Antonios JP, Everson RG and Liau LM:
Dendritic cell immunotherapy for brain tumors. J Neurooncol.
123:425–432. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Liau LM, Prins RM, Kiertscher SM, Odesa
SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS,
Cloughesy TF, et al: Dendritic cell vaccination in glioblastoma
patients induces systemic and intracranial T-cell responses
modulated by the local central nervous system tumor
microenvironment. Clin Cancer Res. 11:5515–5525. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Fadul CE, Fisher JL, Hampton TH, Lallana
EC, Li Z, Gui J, Szczepiorkowski ZM, Tosteson TD, Rhodes CH,
Wishart HA, et al: Immune response in patients with newly diagnosed
glio-blastoma multiforme treated with intranodal autologous tumor
lysate-dendritic cell vaccination after radiation chemotherapy. J
Immunother. 34:382–389. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Sampson JH, Archer GE, Mitchell DA,
Heimberger AB, Herndon JE II, Lally-Goss D, McGehee-Norman S,
Paolino A, Reardon DA, Friedman AH, et al: An epidermal growth
factor receptor variant III-targeted vaccine is safe and
immunogenic in patients with glioblastoma multiforme. Mol Cancer
Ther. 8:2773–2779. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Sakai K, Shimodaira S, Maejima S, Udagawa
N, Sano K, Higuchi Y, Koya T, Ochiai T, Koide M, Uehara S, et al:
Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in
patients with recurrent malignant glioma. J Neurosurg. 123:989–997.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Laurell A, Lönnemark M, Brekkan E,
Magnusson A, Tolf A, Wallgren AC, Andersson B, Adamson L, Kiessling
R and Karlsson-Parra A: Intratumorally injected pro-inflammatory
allogeneic dendritic cells as immune enhancers: A first-in-human
study in unfavourable risk patients with metastatic renal cell
carcinoma. J Immunother Cancer. 5:52. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Karbach J, Gnjatic S, Biskamp M, Atmaca A,
Weidmann E, Brandt K, Wahle C, Bernhard H, Knuth A and Jäger E:
Long-term complete remission following radiosurgery and
immunotherapy in a melanoma patient with brain metastasis:
Immunologic correlates. Cancer Immunol Res. 2:404–409. 2014.
View Article : Google Scholar : PubMed/NCBI
|
